Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications

Source: J Am Acad Dermatol

Bordeaux JS, Martires KJ, Goldberg D, Pattee SF, Fu P, Maloney ME; Journal of the American Academy of Dermatology (Jul 2011)

Tags:

clopidogrel

warfarin

Read more...

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD; New England Journal of Medicine (NEJM) (Jun 2011)

Source: N Engl J Med

Tags:

dacarbazine

ipilimumab

Melanoma

Read more...

Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: Report of 7 cases and a review of the literature

Yuen WY, Jonkman MF; Journal of the American Academy of Dermatology (May 2011)

Source: J Am Acad Dermatol

Tags:

BACKGROUND:  Squamous cell carcinoma (SCC) is the most severe complication and most common cause of death in patients with recessive dystrophic epidermolysis bullosa. The risk of developing SCC among patients with junctional epidermolysis bullosa (JEB) is unclear from the literature; however, in our center we noticed an unexpected number of SCCs among adult patients with JEB.

Read more...

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, the BRIM-3 Study Group; New England Journal of Medicine (NEJM) (Jun 2011)

Source: N Engl J Med

Tags:

dacarbazine

Melanoma

vemurafenib

Read more...